VBL Therapeutics to Host a Key Opinion Leader Event on Novel New Targets and Immunotherapeutic Approaches to Oncology

TEL AVIV, Israel, March 23, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) announced today that it will be hosting a Key Opinion Leader breakfast on new targets and immunotherapeutic approaches to oncology, on April 6, 2017 in New York City.

The meeting will feature a presentation by key opinion leader Ramy Ibrahim, MD (Parker Institute), who will discuss the current treatment landscape and unmet medical need for new targets and therapeutic approaches in oncology. Dr. Ibrahim will be available to answer questions following the breakfast.

VBL Therapeutics' management team will provide an overview of the Company's programs in oncology, including new platform technology targeting MOSPD2 for immune/oncology applications, as well as the Company's research and clinical development of lead candidate VB-111 in patients with recurrent glioblastoma, ovarian, and thyroid cancers.

Ramy Ibrahim, MD, currently serves as Vice President, Clinical Development at the Parker Institute for Cancer Immunotherapy, a collaboration between the country’s leading immunologists and cancer centers. He is a trained medical oncologist, who conducted bench and clinical immunotherapy research at the cancer vaccine branch of the National Cancer Institute (NCI). Dr. Ibrahim also helped develop some of the first breakthrough treatments in the field during his tenure at Bristol-Myers Squibb and MedImmune/AstraZeneca. At AstraZeneca, Dr. Ibrahim was the vice president of clinical development for Immuno-Oncology, leading the team developing multiple immunotherapies. Molecules developed under his leadership included durvalumab (anti-PDL1 antibody) and tremelimumab (anti-CTLA4 antibody) both with single drug and combination therapies with a focus on registrational studies in multiple indications including lung cancer, bladder cancer and head and neck cancer.  As a member of the Bristol-Myers Squibb Immuno-Oncology program, he served on the Yervoy (ipilimumab) clinical team supporting the program from early phase II through multiple global launches of the first FDA-approved immune checkpoint inhibitor. In addition, he played a key role in early development for nivolumab (PD-1), PDL1, and CD137 antibody.

This event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only.  Please RSVP in advance if you plan to attend, as space is limited.  To reserve a spot, please reply to this email or contact LifeSci Advisors, LLC at Mac@LifeSciAdvisors.com. A live and archived webcast of the event, with slides, will be available at http://lifesci.rampard.com/20170406/reg.jsp and on the Investors section of the Company’s website at http://www.vblrx.com

About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >200 cancer patients and we have observed its efficacy signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a Phase 3 pivotal trial for recurrent Glioblastoma, conducted under an FDA Special Protocol Assessment (SPA).

Forward Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to”, “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. These forward-looking statements include, but are not limited to, statements regarding the clinical development of ofranergene obadenovec (VB-111) and its therapeutic potential, clinical trials and clinical results, including the timing thereof, and our other pipeline candidates, including those targeting MOSPD2. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and the risk that historical clinical trial results may not be predictive of future trial results. A further list and description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. VBL Therapeutics undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

CONTACT: INVESTOR CONTACT:
Michael Rice
LifeSci Advisors, LLC
(646) 597-6979

Ads